nach oben

Pituitary

Erschienen in:

01.02.2015

The clinical and cardiometabolic effects of d3-growth hormone receptor polymorphism in acromegaly

verfasst von: Nese Cinar, Selcuk Dagdelen, Hikmet Yorgun, Ugur Canpolat, Giray Kabakçı, Tomris Erbas

Erschienen in: Pituitary | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Exon 3-deleted GH receptor variant (d3-GHR) is associated with increased responsiveness to exogenous GH. The aim of this study was to determine the effect of d3-GHR polymorphism on the GH/IGF-1 relationship, clinical parameters, and comorbidity in acromegalic patients.

Methods

The study included 118 acromegalic patients (61 female and 57 male; mean age: 50.3 ± 12.2 years) and 108 healthy controls (94 female and 14 male: mean age: 41.1 ± 11.1 years). The prevalence of GHR genotypes was evaluated via PCR.

Results

In all, 71 (60.2 %) patients had the fl/fl-GHR genotype, 40 (33.9 %) were heterozygous for the fl/d3-GHR genotype, and 7 (5.9 %) were homozygous for the d3/d3-GHR genotype. The prevalence of fl/fl-GHR, fl/d3-GHR, and d3/d3-GHR genotypes in the control group was 57.4, 29.6, and 13.0 %, respectively—similar prevalences as in the patient group. Patients that were heterozygous and homozygous for the d3 allele were subgrouped (d3-GHR subgroup), and were compared to those with the fl/fl-GHR genotype (fl/fl-GHR subgroup). Anthropometric measures, features of pituitary adenoma, and baseline GH and IGF-1 levels were similar in both subgroups. The prevalence of coronary artery disease, hypertension, hyperlipidemia, type 2 diabetes mellitus, and multinodular goiter did not differ between patient subgroups. In total, 24 (20.3 %) of the patients had cancer and the prevalence of cancer was similar in the d3-GHR (14.9 %) and fl/fl-GHR (23.9 %) subgroups (P = 0.23). More of the acromegalic patients that were d3 carriers had discordant GH and IGF-1 levels at baseline and post surgery, but the difference was not significant. A significant correlation between basal GH and IGF-1 levels was observed only in the patients with the fl/fl-GHR genotype (R² = 0.227, P < 0.001).

Conclusion

The d3-GHR variant genotype did not have an effect on clinical features or comorbidity in acromegalic patients, but it might play a role in GH/IGF-1 level discordance in acromegaly.

Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25(1):102–152PubMedCrossRef

Dogan S, Atmaca A, Dagdelen S, Erbas B, Erbas T (2013) Evaluation of thyroid diseases and differentiated thyroid cancer in acromegalic patients. Endocrine. doi:10.1007/s12020-013-9981-3

Beckers A, Aaltonen LA, Daly AF, Karhu A (2013) Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. Endocr Rev 34(2):239–277. doi:10.1210/er.2012-1013 PubMedCentralPubMedCrossRef

Cannavo S, Ferrau F, Ragonese M, Curto L, Torre ML, Magistri M, Marchese A, Alibrandi A, Trimarchi F (2010) Increased prevalence of acromegaly in a highly polluted area. Eur J Endocrinol 163(4):509–513. doi:10.1530/EJE-10-0465 PubMedCrossRef

Leung DW, Spencer SA, Cachianes G, Hammonds RG, Collins C, Henzel WJ, Barnard R, Waters MJ, Wood WI (1987) Growth hormone receptor and serum binding protein: purification, cloning and expression. Nature 330(6148):537–543. doi:10.1038/330537a0 PubMedCrossRef

Pantel J, Machinis K, Sobrier ML, Duquesnoy P, Goossens M, Amselem S (2000) Species-specific alternative splice mimicry at the growth hormone receptor locus revealed by the lineage of retroelements during primate evolution. J Biol Chem 275(25):18664–18669. doi:10.1074/jbc.M001615200 PubMedCrossRef

Dos Santos C, Essioux L, Teinturier C, Tauber M, Goffin V, Bougneres P (2004) A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone. Nat Genet 36(7):720–724. doi:10.1038/ng1379 PubMedCrossRef

Audi L, Esteban C, Carrascosa A, Espadero R, Perez-Arroyo A, Arjona R, Clemente M, Wollmann H, Fryklund L, Parodi LA (2006) Exon 3-deleted/full-length growth hormone receptor polymorphism genotype frequencies in Spanish short small-for-gestational-age (SGA) children and adolescents (n = 247) and in an adult control population (n = 289) show increased fl/fl in short SGA. J Clin Endocrinol Metab 91(12):5038–5043. doi:10.1210/jc.2006-0828 PubMedCrossRef

Sobrier ML, Duquesnoy P, Duriez B, Amselem S, Goossens M (1993) Expression and binding properties of two isoforms of the human growth hormone receptor. FEBS Lett 319(1–2):16–20PubMedCrossRef

10.

Binder G, Baur F, Schweizer R, Ranke MB (2006) The d3-growth hormone (GH) receptor polymorphism is associated with increased responsiveness to GH in Turner syndrome and short small-for-gestational-age children. J Clin Endocrinol Metab 91(2):659–664. doi:10.1210/jc.2005-1581 PubMedCrossRef

11.

Wickelgren RB, Landin KL, Ohlsson C, Carlsson LM (1995) Expression of exon 3-retaining and exon 3 excluding isoforms of the human growth hormone-receptor is regulated in an interindividual, rather than a tissue specific, manner. J Clin Endocrinol Metab 80(7):2154–2157PubMed

12.

Jorge AA, Marchisotti FG, Montenegro LR, Carvalho LR, Mendonca BB, Arnhold IJ (2006) Growth hormone (GH) pharmacogenetics: influence of GH receptor exon 3 retention or deletion on first-year growth response and final height in patients with severe GH deficiency. J Clin Endocrinol Metab 91(3):1076–1080. doi:10.1210/jc.2005-2005 PubMedCrossRef

13.

Carrascosa A, Esteban C, Espadero R, Fernandez-Cancio M, Andaluz P, Clemente M, Audi L, Wollmann H, Fryklund L, Parodi L (2006) The d3/fl-growth hormone (GH) receptor polymorphism does not influence the effect of GH treatment (66 microg/kg per day) or the spontaneous growth in short non-GH deficient small-for-gestational-age children: results from a two-year controlled prospective study in 170 Spanish, patients. J Clin Endocrinol Metab 91(9):3281–3286. doi:10.1210/jc.2006-0685 PubMedCrossRef

14.

Blum WF, Machinis K, Shavrikova EP, Keller A, Stobbe H, Pfaeffle RW, Amselem S (2006) The growth response to growth hormone (GH) treatment in children with isolated GH deficiency is independent of the presence of the exon 3-minus isoform of the GH receptor. J Clin Endocrinol Metab 91(10):4171–4174. doi:10.1210/jc.2006-0063 PubMedCrossRef

15.

van der Klaauw AA, van der Straaten T, Baak-Pablo R, Biermasz NR, Guchelaar HJ, Pereira AM, Smit JW, Romijn JA (2008) Influence of the d3-growth hormone (GH) receptor isoform on short-term and long term treatment response to GH replacement in GH-deficient adults. J Clin Endocrinol Metab 93(7):2828–2834. doi:10.1210/jc.2007-2728 PubMedCrossRef

16.

Moyes VJ, Walker DM, Owusu-Antwi S, Maher KT, Metherell L, Akker SA, Monson JP, Clark AJ, Drake WM (2010) d3-GHR genotype does not explain heterogeneity in GH responsiveness in hypopituitary adults. Clin Endocrinol (Oxf) 72(6):807–813. doi:10.1111/j.1365-2265.2009.03768.x CrossRef

17.

Barbosa EJ, Palming J, Glad CA, Filipsson H, Koranyi J, Bengtsson BA, Carlsson LM, Boguszewski CL, Johannsson G (2009) Influence of the exon 3-deleted/full-length growth hormone (GH) receptor polymorphism on the response to GH replacement therapy in adults with severe GH deficiency. J Clin Endocrinol Metab 94(2):639–644. doi:10.1210/jc.2008-0323 PubMedCrossRef

18.

Adetunji OR, MacFarlane IA, Javadpour M, Alfirevic A, Pirmohamed M, Blair JC (2009) The d3/fl-GH receptor gene polymorphism does not influence quality of life and body composition in GH-deficient adults receiving GH replacement therapy. Eur J Endocrinol 161(4):541–546. doi:10.1530/EJE-09-0405 PubMedCrossRef

19.

Sorensen K, Aksglaede L, Munch-Andersen T, Aachmann-Andersen NJ, Leffers H, Helge JW, Hilsted L, Juul A (2009) Impact of the growth hormone receptor exon 3 deletion gene polymorphism on glucose metabolism, lipids, and insulin-like growth factor-I levels during puberty. J Clin Endocrinol Metab 94(8):2966–2969. doi:10.1210/jc.2009-0313 PubMedCrossRef

20.

Strawbridge RJ, Karvestedt L, Li C, Efendic S, Ostenson CG, Gu HF, Brismar K (2007) GHR exon 3 polymorphism: association with type 2 diabetes mellitus and metabolic disorder. Growth Horm IGF Res 17(5):392–398. doi:10.1016/j.ghir.2007.04.005 PubMedCrossRef

21.

Horan M, Newsway V, Lewis MD, Easter TE, Rees DA, Mahto A, Millar DS, Procter AM, Scanlon MF, Wilkinson IB, Hall IP, Wheatley A, Blakey J, Bath PM, Cockcroft JR, Krawczak M, Cooper DN (2006) Genetic variation at the growth hormone (GH1) and growth hormone receptor (GHR) loci as a risk factor for hypertension and stroke. Hum Genet 119(5):527–540. doi:10.1007/s00439-006-0166-5 PubMedCrossRef

22.

Audi L, Carrascosa A, Esteban C, Fernandez-Cancio M, Andaluz P, Yeste D, Espadero R, Granada ML, Wollmann H, Fryklund L (2008) The exon 3-deleted/full-length growth hormone receptor polymorphism does not influence the effect of puberty or growth hormone therapy on glucose homeostasis in short non-growth hormone-deficient small-for-gestational-age children: results from a two-year controlled prospective study. J Clin Endocrinol Metab 93(7):2709–2715. doi:10.1210/jc.2008-0150 PubMedCrossRef

23.

Mercado M, Gonzalez B, Sandoval C, Esquenazi Y, Mier F, Vargas G, de los Monteros AL, Sosa E (2008) Clinical and biochemical impact of the d3 growth hormone receptor genotype in acromegaly. J Clin Endocrinol Metab 93(9):3411–3415. doi:10.1210/jc.2008-0391 PubMedCrossRef

24.

Schmid C, Krayenbuehl PA, Bernays RL, Zwimpfer C, Maly FE, Wiesli P (2007) Growth hormone (GH) receptor isoform in acromegaly: lower concentrations of GH but not insulin-like growth factor-1 in patients with a genomic deletion of exon 3 in the GH receptor gene. Clin Chem 53(8):1484–1488. doi:10.1373/clinchem.2007.085712 PubMedCrossRef

25.

Montefusco L, Filopanti M, Ronchi CL, Olgiati L, La-Porta C, Losa M, Epaminonda P, Coletti F, Beck-Peccoz P, Spada A, Lania AG, Arosio M (2010) d3-Growth hormone receptor polymorphism in acromegaly: effects on metabolic phenotype. Clin Endocrinol (Oxf) 72(5):661–667. doi:10.1111/j.13652265.2009.03703.x CrossRef

26.

Wassenaar MJ, Biermasz NR, Pereira AM, van der Klaauw AA, Smit JW, Roelfsema F, van der Straaten T, Cazemier M, Hommes DW, Kroon HM, Kloppenburg M, Guchelaar HJ, Romijn JA (2009) The exon-3 deleted growth hormone receptor polymorphism predisposes to long-term complications of acromegaly. J Clin Endocrinol Metab 94(12):4671–4678. doi:10.1210/jc.2009-1172 PubMedCrossRef

27.

Turgut S, Akin F, Ayada C, Topsakal S, Yerlikaya E, Turgut G (2012) The growth hormone receptor polymorphism in patients with acromegaly: relationship to BMI and glucose metabolism. Pituitary 15(3):374–379. doi:10.1007/s11102-011-0329-9 PubMedCrossRef

28.

Brzana JA, Yedinak CG, Delashaw JB, Gultelkin HS, Cook D, Fleseriu M (2012) Discordant growth hormone and IGF-1 levels post pituitary surgery in patients with acromegaly naive to medical therapy and radiation: what to follow, GH or IGF-1 values? Pituitary 15(4):562–570. doi:10.1007/s11102-011-0369-1 PubMedCrossRef

29.

Alexopoulou O, Bex M, Abs R, T’Sjoen G, Velkeniers B, Maiter D (2008) Divergence between growth hormone and insulin-like growth factor-i concentrations in the follow-up of acromegaly. J Clin Endocrinol Metab 93(4):1324–1330. doi:10.1210/jc.2007-2104 PubMedCrossRef

30.

Melmed S, Jackson I, Kleinberg D, Klibanski A (1998) Current treatment guidelines for acromegaly. J Clin Endocrinol Metab 83(8):2646–2652PubMed

31.

Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S (2000) Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85(2):526–529. doi:10.1210/jcem.85.2.6363 PubMed

32.

Tiryakioglu O, Kadiolgu P, Canerolgu NU, Hatemi H (2003) Age dependency of serum insulin: like growth factor (IGF)-1 in healthy Turkish adolescents and adults. Indian J Med Sci 57(12):543–548PubMed

33.

Mercado M, Espinosa de los Monteros AL, Sosa E, Cheng S, Mendoza V, Hernandez I, Sandoval C, Guinto G, Molina M (2004) Clinical-biochemical correlations in acromegaly at diagnosis and the real prevalence of biochemically discordant disease. Horm Res 62(6):293–299. doi:10.1159/000082032 PubMedCrossRef

34.

Bianchi A, Giustina A, Cimino V, Pola R, Angelini F, Pontecorvi A, De Marinis L (2009) Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly. J Clin Endocrinol Metab 94(6):2015–2022. doi:10.1210/jc.2008-1337 PubMedCrossRef

35.

Kamenicky P, Dos Santos C, Espinosa C, Salenave S, Galland F, Le Bouc Y, Maison P, Bougneres P, Chanson P (2009) D3 GH receptor polymorphism is not associated with IGF1 levels in untreated acromegaly. Eur J Endocrinol 161(2):231–235. doi:10.1530/EJE-09-0053 PubMedCrossRef

36.

Filopanti M, Olgiati L, Mantovani G, Corbetta S, Arosio M, Gasco V, De Marinis L, Martini C, Bogazzi F, Cannavo S, Colao A, Ferone D, Arnaldi G, Pigliaru F, Peri A, Angeletti G, Jaffrain-Rea ML, Lania AG, Spada A (2012) Growth hormone receptor variants and response to pegvisomant in monotherapy or in combination with somatostatin analogs in acromegalic patients: a multicenter study. J Clin Endocrinol Metab 97(2):E165–E172. doi:10.1210/jc.2011-1769 PubMedCrossRef

37.

Dagdelen S, Cinar N, Erbas T (2013) Increased thyroid cancer risk in acromegaly. Pituitary. doi:10.1007/s11102-013-0501-5 PubMed

38.

Wagner K, Hemminki K, Grzybowska E, Bermejo JL, Butkiewicz D, Pamula J, Pekala W, Forsti A (2006) Polymorphisms in the growth hormone receptor: a case-control study in breast cancer. Int J Cancer 118(11):2903–2906. doi:10.1002/ijc.21703 PubMedCrossRef

Titel: The clinical and cardiometabolic effects of d3-growth hormone receptor polymorphism in acromegaly
verfasst von: Nese Cinar
Selcuk Dagdelen
Hikmet Yorgun
Ugur Canpolat
Giray Kabakçı
Tomris Erbas
Publikationsdatum: 01.02.2015
Verlag: Springer US
Erschienen in: Pituitary / Ausgabe 1/2015
Print ISSN: 1386-341X
Elektronische ISSN: 1573-7403
DOI: https://doi.org/10.1007/s11102-014-0564-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2015

Combined high-field intraoperative magnetic resonance imaging and endoscopy increase extent of resection and progression-free survival for pituitary adenomas

Evaluation of hypothalamic–pituitary function in children following acute bacterial meningitis

Towards a better quality of life (QoL) for patients with pituitary diseases: results from a focus group study exploring QoL

Expression of the pituitary stem/progenitor marker GFRα2 in human pituitary adenomas and normal pituitary

Long-term remission and recurrence rate in a cohort of Cushing’s disease: the need for long-term follow-up